A Phase I Study of RO7428731 in People with Glioblastoma

Share

Full Title

An Open-Label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants with Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III

Purpose

The purpose of this study is to find the highest dose of the investigational drug RO7428731 that can be given safely in people with glioblastoma that makes a protein called EGFRvIII. RO7428731 targets EGFRvIII on glioblastoma cells and also helps the immune system find and kill cancer cells. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have glioblastoma that makes the EGFRvIII protein and has not yet been treated.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Ingo Mellinghoff at 646-888-2766.

Protocol

22-258

Phase

I

Disease Status

Newly Diagnosed

Investigator

Co-Investigators